Drug Type Small molecule drug |
Synonyms CpAM |
Target |
Mechanism Capsid inhibitors(Capsid protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 2 | CN | 13 Apr 2020 | |
Hepatitis B | Discovery | CN | 24 Aug 2018 |
Phase 1 | - | 22 | (Mass Balance (MB) Cohort) | emgzvktyjn(idyrgytqsd) = pakmhmdput tzdoifmhne (xihfzbfskm, wfgxgqcfbm - dbtabmnasq) View more | - | 15 Jul 2024 | |
(Absolute Bioavailability (BA) Cohort) | fxsfdekhld(chqdzyjeae) = rqtxuimlqi yisydklztr (ysfjkilqqg, affudwdqyi - dvchotovdd) View more | ||||||
Phase 1 | - | RO7049389+NUC | xqfzggxmnt(rjudvesfno) = ALT elevations resolved spontaneously and were not accompanied by significant changes in liver function btjvvycnce (obnyysfgtp ) View more | - | 25 Jun 2022 | ||
RO7049389+NUC+Peg-IFN-alpha | |||||||
Phase 1 | - | 18 | ogmtvalioy(fvtjebpemy) = cxincqzduv fqhlmtzymq (dxtzhqiczs, uvhtwcxvrj - ldketztpus) View more | - | 10 Jan 2020 | ||
Phase 1 | - | taazhxxfdk(ikzvpgcysg) = A total of 39 adverse events (AEs) were reported in 14 of 22 HBV patients, 3 patients had treatment emergent Grade 3 ALT/AST increase which resolved without treatment in follow-up. One pre- dose SAE was reported and the patient was replaced. No AEs leading to drug discontinuation were reported and no clinically significant changes in any safety parameters tested were observed. sclxnibksa (wkkezchbau ) | Positive | 12 Apr 2019 | |||